OTIC Otonomy, Inc.

15.55
+0.5  (3.32%)
Previous Close 15.05
Open 15.05
Price To book 2.11
Market Cap 469.52M
Shares 30,194,000
Volume 146,995
Short Ratio 10.49
Av. Daily Volume 180,473

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved December 11 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Second Phase 3 trial initiated March 2016. Data from both Phase 3 trials due 2H 2017.
OTO-104 AVERTS-1 and AVERTS-2
Ménière's disease
Phase 2 trial completed October 2016. End of Phase 2 meeting planned with FDA 1H 2017.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Phase 3 trial met primary endpoint - January 5, 2017. sNDA filing to be submitted 1H 2017.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
  2. OTONOMY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  3. Otonomy Provides Corporate and Product Pipeline Update
  4. Otonomy, Inc. breached its 50 day moving average in a Bullish Manner : OTIC-US : January 6, 2017
  5. Why These 5 Biopharma Stocks Are Making Massive Gains on Thursday
  6. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  7. Otonomy's ear infection drug succeeds in late-stage trial
  8. Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO® in Patients with Acute Otitis Externa
  9. What We’re Watching In Biotech For January: Otonomy Inc (OTIC) And TESARO Inc (TSRO)
  10. Otonomy to Present at the J.P. Morgan Healthcare Conference
  11. Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : December 19, 2016
  12. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 16, 2016
  13. Hedge Funds Are Selling Otonomy Inc (OTIC)
  14. ETFs with exposure to Otonomy, Inc. : December 2, 2016
  15. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : December 1, 2016
  16. OTONOMY, INC. Files SEC form 8-K, Regulation FD Disclosure
  17. Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer
  18. Otonomy to Present at Piper Jaffray Healthcare Conference
  19. Edited Transcript of OTIC earnings conference call or presentation 3-Nov-16 8:30pm GMT
  20. OTONOMY, INC. Financials